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Cellular localization of tissue kallikrein and kallistatin mRNAs in
human kidney. The renal kallikrein-kinin system has been implicated in
the regulation of blood pressure and sodium/water excretion. The activity
of renal kallikrein is controlled by a number of factors in vivo. Kallistatin
is a newly identified serine proteinase inhibitor (serpin) which binds to
tissue kallikrein and inhibits its enzymatic activity in vitro. To understand
the role of kallistatin in modulating tissue kallikrein's function in vivo, we
examined the anatomical relationship between human tissue kallikrein
and kallistatin in the kidney by in situ hybridization histochemistry. Tissue
kallikrein and kallistatin gene transcripts were identified using digoxige-
nm-labeled riboprobes at the cellular level. Antisense and sense ribo-
probes corresponding to the 3' region of the human kallikrein and
kallistatin mRNAs were synthesized by in vitro transcription and used for
hybridization. Using an antisense kallikrein riboprobe, sites of kallikrein
synthesis were localized in the distal tubules, collecting ducts and Henle's
loops of the kidney. To a lesser degree, juxtaglomerular cells were also
stained. Kallistatin mRNA was found at the same sites where kallikrein
mRNA was localized. The most intense signals of both kallikrein and
kallistatin were seen in the distal tubules and collecting ducts. Hybridiza-
tion was specific for the target mRNA since sense kallikrein or kallistatin
riboprobe did not bind to the sections. Immunoreactive human renal
kallikrein and kallistatin levels were measured in the kidney and urine by
immunoassays using specific antibodies. Co-localization of kallikrein and
kallistatin mRNA in the kidney suggests a potential role of kallistatin in
regulating tissue kallikrein's function.
Tissue kallikreins (EC 3.4.21.35) belong to a subgroup of highly
homologous serine proteinases which liberate kinin peptides from
kininogen substrates by limited proteolysis [1—3]. Kinins mediate
a broad spectrum of biological effects including vasodilation,
inflammation, pain, and smooth muscle contraction and relax-
ation. Localization of tissue kallikrein and/or its mRNA has been
shown in various mammalian tissues including kidney, salivary
glands, pancreas, brain, pituitary gland, skeletal muscle, heart and
vasculature [3, 4]. The pattern of tissue-specific expression is
different among kallikrein gene family members [4, 5]. The
apparent substrate specificity of individual kallikreins suggests
that kallikrein gene family members process various polypeptide
precursors in addition to kininogen [3, 5] and may be synthesized
in a coordinated, tissue-specific manner with their particular
prohormone substrates.
Previous immunohistochemical studies showed that in human
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kidney, tissue kallikrein is localized at the following sites: reab-
sorption droplets of the proximal and distal tubules [6], renal
interstitium [7], connecting tubule cells [8] and collecting ducts
[9]. Also, Vio, Figueroa and Caorsi [10] reported that tissue
kallikrein is localized in the connecting tubules, but not in the
proximal tubules. Immunoreactive low molecular weight kinino-
gen has been localized in the distal tubules and collecting ducts of
human kidney [8, 11]. Anatomical co-localization of kallikrein and
the substrate kininogen in the kidney provides the basis for a
functional role of intrarenal kinins in the regulation of blood
pressure and electrolyte balance in the kidney. However, little
information is known regarding the cellular localization of human
tissue kallikrein mRNA in the kidney.
Tissue kallikrein levels are regulated at both the transcriptional
and post-translational levels [4, 5]. In search of endogenous
protein factors modulating tissue kallikrein activity and function,
we have recently isolated and cloned kallikrein-binding proteins in
humans, rats and mice. The kallikrein-binding proteins, or KBPs,
belong to the serine proteinase inhibitor (serpin) superfamily. The
human kallikrein-binding protein gene displays the highest se-
quence homology (46.4%) with human al-antichymotrypsin at
the nucleotide level [12]. The genes encoding rat and mouse
kallikrein-binding proteins also belong to multigene families of
serpins, which are highly homologous to the rodent al-antichy-
motrypsin(s) or mouse contrapsin [13]. The physiological function
of kallikrein-binding proteins is not known at the present time.
However, reduced expression of kallikrein-binding protein in
spontaneously hypertensive rats (SHR) suggests that the kal-
likrein-binding protein may play an important role in the blood
pressure regulation in SHR [14].
The kallikrein-binding protein in humans is designated as
kallistatin or HKBP [151. It is distinct from other serpins with a
unique reactive site dipeptide Pi-Pi' of Phe-Ser [12]. It rapidly
forms an initial reversible complex with tissue kallikrein, which
becomes an irreversible SDS-stable complex. Interaction of kal-
listatin with kallikrein results in the inhibition of kallikrein activity
[15, 16]. The expression of kallistatin has been found in several
tissues including the kidney, aorta, liver, pancreas, stomach, colon,
testis and prostate gland [12], Studies of cellular localization of
kallistatin and its anatomical relationship with tissue kallikrein
and/or kininogen in human kidney and other tissues will lead to an
understanding of the physiological role of kallistatin.
In the present study, we localized kallikrein and kallistatin
mRNAs in human kidney by in situ hybridization histochemistry.
By using their respective antisense riboprobes we found that both
690
Chen et at: Renal kallikrein and kallistatin mRNAs 691
kallikrein and kallistatin are intensively localized in the distal
tubules and collecting ducts of human kidney.
Methods
Human kidney sections
Normal human kidney paraffin blocks were cut into 5 j.m
sections which were mounted onto gelatin-coated slides. The
tissue was collected within six hours after death. Normal human
kidneys were collected from autopsy for immunoassays.
Preparation of riboprobes
A human tissue kallikrein full-length eDNA of 871 base pairs
(bp) [17] was generated using reverse-transcription-polymerase
chain reaction (RT-PCR). This amplified eDNA was cloned into
the pSP73 vector containing the SP6 and T7 viral promoters,
which flank the polycloning site. Tissue kallikrein/pSP73 plasmid
DNA was digested with ApaI/EcoRI (one in the vector and one in
the insert) restriction enzymes and recircularized by self-ligation.
The resulting tissue kallikrein fragment (186 bp) contains 139 bp
of the coding sequence and 47 bp of non-coding sequence in the
3' region of the tissue kallikrein eDNA. A kallistatin eDNA of
1284 bp [12] was cloned similarly by RT-PCR into the pSP73
vector. The kallistatin/pSP73 plasmid DNA was digested with
PstI/HindIII (one in the vector and one in the insert) restriction
enzymes and recircularized by self-ligation. The resulting kallista-
tin cDNA fragment contains the last 153 bp of coding sequence in
the 3' region. The DNA was then linearized by single enzyme
digestion and gel purified.
In vitro transcription was performed using an RNA Labeling Kit
(SP6IT7) (Boehringer-Mannheim). One microgram of linear tem-
plate DNA was used in each labeling reaction. The labeling
reaction components including transcription buffer, NTP sub-
strates, SP6 or T7 RNA polymerase were mixed with the linear-
ized DNA. The mixture was incubated at 37°C for two hours.
During the transcription, digoxigenin-labeled uridine-triphos-
phate (DIG-UTP) was incorporated into the transcription prod-
ucts and was the target for anti-digoxigenin Fab fragments during
the detection step. The transcribed riboprobes were precipitated
by 70% ethanol, dissolved in 100 l diethyl pyrocarbonate-treated
water and stored at —80°C.
In situ hybridization histochemistry
Human kidney sections were pretreated with xylene to remove
the paraffin and rehydrated through a series of decreasing ethanol
solutions (100%, 100%, 95%, 70%, 50%). Tissue sections were
digested with proteinase K (5 jg/ml in 0.1 M Tris-HCI, pH 8.0,
containing 50 mtvi EDTA) for 25 minutes at 37°C and incubated
for 10 minutes in acetic anhydride (0.25% in 0.1 M triethano-
lamine, pH 7.0). The sections were then dehydrated through a
series of increasing ethanol solutions. Hybridization was carried
out overnight at 42°C in a buffer containing 0.3 M NaC1, 20 mM
Tris-HC1, pH 8.0, 5 mrvi EDTA, 50% formamide, 5 X Denhardt's
(50 >< Denhardt's solution = 1% Ficol, 1% polyvinylpyrrolidone,
and 1% bovine serum albumin), 10% dextran sulfate, 100 jig/mI of
herring sperm DNA and yeast tRNA and antisense riboprobes.
After hybridization, the kidney sections were washed at 4 X SSC
(10 X SSC = 3 M NaCI, 0.3 M sodium citrate, pH 7.0) at room
temperature for one hour with one change, 2 X SSC for 10
minutes with one change, and 0.2 x SSC for one hour with one
change. The sections were then incubated with sheep anti-
digoxigenin Fab fragments which were conjugated to alkaline
phosphatase (1:500, Nucleic Acid Detection Kit, Boehringer-
Mannheim, Germany). The color reaction was performed by
incubating the sections with 4.5 jil of NBT (nitroblue tetrazolium
salt), 3.5 jil of X-Phosphate (5-bromo-4-chloro-3-indolyl phos-
phate), and 0.24 mg levamisole in 1 ml of 0.1 M Tris-HCI, pH 9.5,
containing 0.1 M NaC1, and 50 mvt MgCl2. Control sections were
hybridized with either labeled sense riboprobes or labeled anti-
sense riboprobes following RNase A treatment [10 jig/mI RNase
A in phosphate-buffered saline (PBS), pH 7.2 at 37°C for 30 minI.
Tissue extraction and urine collection
Normal human kidney was minced and homogenized in PBS
using a polytron. The homogenate was centrifuged at 600 X g for
20 minutes at 4°C. Sodium deoxycholate (Sigma) was added to the
supernatant to a final concentration of 0.5% (wt/vol). The solution
was incubated at room temperature for 30 minutes followed by
centrifugation at 20,000 x g for 30 minutes at 4°C. The superna-
tant was collected and the protein concentration was determined
as described previously [18] using bovine serum albumin as the
standard.
Human urine was collected over a 24 hour period and then
centrifuged at 600 x g for 15 minutes at 4°C. The supernatant was
collected and stored at —20°C for analysis.
Human urinary kallikrein radioimmunoassay (RIA)
Purified human urinary kallikrein (HUK) was labeled with 125!
using the lodogen (Pierce) method. Radioimmunoassay was
carried out as previously described [19]. Purified HUK standard
(8 to 1000 pg), serially diluted human kidney extracts and urine, in
a total volume of 100 p1, were mixed with 200 p1 of rabbit
anti-HUK polyclonal antibodies (1:400,000 dilution) and 10,000
cpm of 1251-HUK in 100 p1 of phosphate-buffered saline contain-
ing 1% bovine serum albumin. Following incubation, antibody-
bound kallikrein was precipitated by the polyethylene glycol
method and separated from free kallikrein by centrifugation at
5000 rpm, 4°C for 30 minutes.
Enzyme-linked immunosorbent assay (ELISA)
A 96-well microplate was coated with non-labeled kallistatin
IgG (1 jig/ml in PBS, 100 p1/well) at 4°C for overnight. Before
samples were added, the plate was blocked with 200 p1 of PBS
containing 1% of bovine serum albumin at 37°C for one hour and
washed three times with the washing solution (PBS containing
0.1% of Tween-20). Kallistatin standard (0.4 ng to 25 ng/ml),
human urine and kidney extracts, which were diluted in freshly
made dilution buffer (PBS containing 0.05% Tween-20 and 0.5%
gelatin) in a total volume of 100 p1, were added into each well.
The sample addition was done in duplicate. The plate was
incubated at 37°C for 1.5 hours and washed three times with the
washing solution. Biotin-labeled kallistatin IgG [20] was added
into each well at a concentration of 1 jig/mI in a total volume of
100 pi. The plate was incubated at 37°C for one hour and washed
three times with the washing solution. Peroxidase-avidin at a
concentration of 1 jig/mi, 100 p1/well (diluted in the dilution
buffer) was added and incubated at 37°C for 30 minutes. The plate
was washed five times with the washing solution and once with
PBS. Freshly made substrate solution [10 ml of 0.1 M of citrate
acid, pH 4.3, 3 mg of 2,2'-azinobis(3-ethylbenzthiazoline sulfonic
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acid), and 10 1.il of 3% H202] was added into each well (100
islIwelI). After 30 minutes the plate was read with a ELISA reader
at 414 nm for absorbance.
Results
Cellular localization of tissue kallikrein mRNA in human kidney
Using digoxigenin-labeled antisense tissue kallikrein riboprobe,
tissue kallikrein mRNA was localized primarily in the distal
convoluted tubules (D) and collecting ducts (CD) (Fig. 1A).
Kallikrein mRNA was also seen in some juxtaglomerular arte-
rioles (JG). To a lesser degree, staining was observed in epithelial
cells of glomerular capillaries. Occasionally, the Bowman's cap-
sule and the proximal tubules at the urinary pole were stained. In
the medulla (Fig. 1B), collecting ducts (CD), thin segments of
Henle's loops (H) and distal straight tubules (DST) were stained.
Control sections of the cortex and medulla were not stained when
probed with digoxigenin-labeled sense kallikrein riboprobe (Fig. 3
A, B) or when pretreated with RNase A and then probed with
antisense kallikrein riboprobe (data not shown).
Cellular localization of kallistatin mRNA in human kidney
Figure 2 shows the localization of kallistatin mRNA in the distal
convoluted tubules (D), collecting ducts (CD), thin segments of
Henle's loops (H) and distal straight tubules (DST) using anti-
sense kallistatin riboprobe. The majority of staining occurred in
the distal convoluted and straight tubules and collecting ducts.
Similar to the tissue kallikrein mRNA localization, kallistatin
mRNA was seen in some juxtaglomerular arterioles (JG). A small
amount of staining was observed in epithelial cells of glomerular
capillaries, the Bowman's capsule and the proximal tubules at the
urinary pole. Control sections were not stained when probed with
digoxigenin-labeled sense kallistatin riboprobe (Figs. 3A and 3B)
or pretreated with RNase A and then probed with antisense
kallistatin riboprobe (data not shown).
Immunoreactive renal tissue kallikrein and kallistatin
Immunoreactive kallikrein levels in human urine and kidney
were quantified by RIA using specific antibodies to tissue kal-
likrein [191. Kallistatin levels were quantified by an ELISA using
specific antibodies to kallistatin [15]. Figure 4 shows the standard
curve of kallistatin and serial dilutions of human urine and kidney
extracts. Dose-dependent curves of human urine and kidney
extracts are parallel with the kallistatin standard curve, indicating
their immunological identity. The results of tissue kallikrein and
kallistatin levels in human urine and kidney are summarized in
Table 1. Tissue kallikrein levels are 216.6 15.2 pg/mg protein
(mean SE, N = 3) in the kidney and 267.8 30.7 pg/day (mean
SE, N = 11) in urine. Kallistatin levels are 130.7 9.3 ng/mg
protein (mean SE, N = 3) in the kidney and 13.6 2.7 gg/day
(mean SE, N 13) in urine. The results show that renal and
urinary kallikrein and kallistatin can be quantified.
Discussion
In the present study, we localized tissue kallikrein and kallista-
tin mRNA in human kidney using digoxigenin-labeled specific
antisense riboprobes by in situ hybridization histochemistry. The
results show that kallistatin mRNA has a similar cellular distribu-
tion with that of tissue kallikrein in the distal tubules and
collecting ducts of human kidney. Co-localization of tissue kal-
likrein and kallistatin in human kidney suggests that kallistatin
may play a role in regulating kidney function by modulating
kallikrein activity.
In human kidney, tissue kallikrein mRNA was localized in-
tensely in the distal tubules and collecting ducts. This result is
consistent with that of detecting immunoreactive tissue kallikrein
by immunohistochemistry [8—10]. A small amount of staining was
observed in the Bowman's capsule and the proximal tubules at the
urinary pole. The low level staining in these regions may result
from either a low level expression of tissue kallikrein or difficulties
of the riboprobes to access their targets. Staining was also seen in
some juxtaglomerular arterioles and epithelial cells of glomerular
capillaries. Localization of tissue kallikrein mRNA in juxtaglo-
merular cells and glomeruli suggests that kallikrein may play a
role in the regulation of glomerular filtration rate, blood flow and
renin generation for mantaining body fluid homeostasis.
Previous studies showed that tissue kallikrein mRNA was
localized in the rat renal cortex at the vascular pole of the
glomeruli using a rat tissue kallikrein eDNA probe [21]. Experi-
ments with isolated rat glomeruli confirmed that a member of the
kallikrein gene family is present in the glomeruli [22]. Positive
signals observed in the rat glomeruli using tissue kallikrein cDNA
probe may be attributed to the cross-hybridization of the probe
with other rat kallikrein gene family members. The riboprobe
used in detecting human tissue kallikrein mRNA is specific. It has
—67% nucleotide sequence homology to the other two kallikrein
gene members, hKLK2 (hGK1) or hKLK3 (prostate specific
antigen, PSA). The major synthesis site of PSA and hGK1 was
found to be only in the prostate gland [23—25]. The signals
obtained by binding of antisense tissue kallikrein riboprobe in the
kidney by in situ hybridization are not likely attributed to either
hKLK2 or hKLK3 under such stringent hybridizing and washing
conditions used in this study.
Previously we detected kallistatin gene expression in cultured
primary human renal proximal tubular cells using RT-PCR fol-
lowed by Southern blot analysis [12]. In the present study by in situ
hydridization, kallistatin mRNA was also identified in the proxi-
mal tubules with a low amount of staining compared to that in the
distal tubules and collecting ducts. The low signal in the proximal
tubules by the antisense riboprobe may be due to the fact that it
is less sensitive than PCR in detecting gene expression. Another
possibility is that cultured primary renal tubular cells may contain
some distal tubular cells. Identification of the site of synthesis of
kallistatin in the kidney in the vicinity of the tissue kallikrein
mRNA provides evidence that kallistatin may function in vivo to
modulate tissue kallikrein's activity or bioavailability.
Our studies showed that human urine and kidney contain
immunoreactive tissue kallikrein and kallistatin. The quantity of
tissue kallikrein or kallistatin measured in RIA or ELISA repre-
sents total immunoreactive kallikrein or kallistatin including free
and bound forms. The excretion of human tissue kallikrein and
kallistatin in urine indicates the renal origin of urinary kallikrein
and kallistatin. This hypothesis is further supported by locating
tissue kallikrein and kallistatin mRNA in the distal tubules and
collecting ducts. Table 1 shows the relatively low tissue kallikrein
levels, compared to that of kallistatin, in the kidney. This may be
attributed to rapid secretion of kallikrein into the urine. The same
phenomenon was observed in the synthesis and secretion of other
secretory proteins such as rat kallikrein-binding protein, rat
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Fig. 1. Cellular localization of human tissue kallikrein mRNA in the kidney. The section was hybridized with digoxigenin-labeled antisense tissue kallikrein
riboprobe and detected with anti-digoxigenin Fab fragments. Tissue kallikrein mRNA is seen in the distal convoluted tubules (D) and distal straight
tubules (DST), collecting ducts (CD), juxtaglomerular arterioles (JO) and thin segments of Henle's loops (H). The majority of the signal is seen in the
distal tubules and collecting ducts. G: glomerulus. A. Cortex. B. Medulla (magnification X200).
kininogen and al-antitrypsin [141. These three hepatocyte proteins It has been shown that human urinary (or renal) kallikrein
have high mRNA levels in the liver but their protein levels in the liver levels are reduced in hypertensive patients [26] and that high
are very low since they are rapidly secreted into the circulation. urinary kallikrein activity is associated with a protective effect
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Fig. 2. Cellular localization of human kallistatin mRNA in the kidney. Using digoxigenin-labeled antisense kallistatin riboprobe, kallistatin mRNA is
localized in the distal convoluted tubules (D), distal straight tubules (DST), collecting ducts (CD), juxtaglomerular arterioles (JO), thin segments of
Hcnle's loops (H). Darker staining is seen in the distal tubules and collecting ducts. 0: glomerulus. A. Cortex; B. Medulla (magnification X200).
against hypertension 27I. Reduced urinary kallikrein or kinin been linked with blood pressure regulation by restriction fragment
excretion has also been described in a number of genetically length polymorphisms and co-segregation studies in genetically
hypertensive rats [28, 29]. In addition, rat tissue kallikrein has hypertensive rats [30, 31J. These findings suggest that low renal
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Fig. 3. Control sect ion of human kidney. The section was incubated with both digoxigenin-labeled sense kallikrein and
kallistatin riboprobes. No signals were observed. Hybridization and immunodectection conditions were the same as described
in the text. G: glomerulus. A. Cortex; B. Medulla (magnification, X200).
kallikrein levels may contribute to the pathogenesis of hyperten- kallikrein function in vivo. Therefore, alteration of urinary kal-
sion. Kallistatin, which binds to human tissue kallikrein and listatin levels may serve as an index for the renal kallikrein-kinin
inhibits its enzyme activity, is a potential regulator of renal system in patients with hypertensive diseases. This hypothesis is
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Fig. 4. Enzyme-linked immunosorbent assay of human kallistatin in the
kidney and urine. The standard curve of kallistatin which ranges from 0.4
to 25.0 ng/ml is shown by solid circles and serial dilutions of human kidney
extracts and urine are shown by solid triangles and squares, respectively.
Kidney' Urine
Kallikrein 216.6 15.2 pg/mg 267.8 30.7 sgIday
Kallistatin 130.7 9.3 ng/mg 13.6 2.7 jg/day
Values represent mean SE (N 11 or 13, urine; N = 3, kidney).
"Specific activity is expressed as immunoreactive kallikrein or kallistatin
levels per mg protein in the kidney.
supported by the finding that rat kallikrein-binding protein
mRNA is expressed mostly in the collecting duct of the kidney and
its mRNA levels were significantly decreased in the kidney of
spontaneously hypertensive rats [32].
Studies have shown that the renal kallikrein-kinin system is
involved in the regulation of sodium/water excretion and arterial
blood pressure [33]. The kidney plays a major role in the
regulation of body sodium and fluid homeostasis. Failure of the
renal handling of sodium and water may lead to renal disorders. A
number of studies have shown that the release of renal tissue
kallikrein is associated with several factors such as high sodium or
potassium intake, antidiuretic hormone (arginine vasopressin)
effect and neural control [34—361. Intrarenal production of kinins
may increase local renal blood flow, glomerular filtration and
electrogenic ion transport [37, 38]. Another possibility is that both
kinin and tissue kallikrein may stimulate renin release to produce
angiotensin II in order to counter-balance the function of kinin,
thereby maintaining renal homeostasis [39]. The localization of
tissue kallikrein, kininogen and kallistatin in the distal tubules and
collecting ducts suggests that they may function as an autocrine!
paracrine system.
Kallistatin as an endogenous inhibitor of tissue kallikrein may
act to modulate kallikrein's activity and function in renal cells.
Studies on the anatomical relationship and physiological changes
of renal and/or urinary kallistatin and kallikrein in kidney diseases
may provide insights into further understanding the functional
role and regulatory mechanisms of kallistatin.
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Appendix
Abbreviations are: RT-PCR, reverse transcription-polymerase chain
reaction; RIA, radioimmunoassay; ELISA, enzyme-linked immunosor-
bent assay; HUK, human urinary kallikrein; PBS, phosphate-buffered
saline; NBT, nitroblue tetrazolium salt; X-Phosphate, 5-bromo-4-chloro-
3-indolyl phosphate.
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